Inspur Information Releases 2020 Global Computing Index Report
26.2.2021 11:07:00 EET | Business Wire | Press release
Inspur Information, a leading IT infrastructure solutions provider, has sponsored an International Data Corporation (IDC) white paper on the 2020 Global Computing Index (henceforth referred to as The Report). As the world’s first index report on computing, The Report unveils the relationship between computing power and economic development and serves as a reference for the outlook of the global digital economy.
Global digital transformation has entered a phase marked by exponential growth in innovation, with the size of the digital economy projected to continue on an upward trend. As a key factor that underlies digital technology development, computing is now defining the productivity of the digital economy era. According to The Report, economic growth directly correlates with the development of computing—one point of growth in the computing index translates to a 3.3‰ rise in the size of the digital economy and a 1.8‰ growth in GDP. Specifically, AI computing market share is projected to continue on this upward trajectory. Research on computing markets in sample countries shows that AI computing market share has grown from 7% in 2015 to 12% of the overall computing market in 2019 and is expected to reach 23% in 2024. With the largest number of hyper-scale data centers in the world, the United States has demonstrated its strong infrastructure support for computing power growth, ranking first on the index ranking with a score of 75. In second place with a score of 66 is China, followed by Japan (55), Germany (52), and the United Kingdom (47).
The Global Computing Index represents a year-long joint effort by Inspur Information and IDC. The Report, covering Australia, Brazil, China, France, Germany, Japan, Russia, South Africa, the United Kingdom, and the United States, offers a comprehensive assessment of computing power across four dimensions: computing capacity, computing efficiency, application level, and infrastructure support.
Zhang Dong, vice president of Inspur Information, noted that "the application of emerging technologies, especially AI, will be driving the advancement of computing. As the volume of data and the complexity of algorithms continues to rise, computing will be the determining factor for the AI development ceiling.”
Computing Defines Productivity in the Digital Economy Era; Synchronized Development of Emerging Technology Applications and Computing will Foster Economic Growth
The development of emerging technologies and computing are mutually beneficial in that computing power provides infrastructure support for emerging technologies, which in turn pushes forward the evolution of computing. IoT, AI, and big data are among the major emerging technologies.
In 2020, the global spending on AI by enterprises was forecast to be US$49.87 billion, and this number is estimated to reach US$96.28 billion by 2023. The development of AI is driven by the advancement in computing, data, and algorithms, and sufficient computing power is necessary for the processing of large amounts of data using complex algorithms. The widespread application of IoT will give rise to the fast advancement of edge computing, which has already reshaped IT infrastructure and will revolutionize computing, storage, and networks. Cloud computing is the most important means for improving computing efficiency. IT infrastructure that supports same-pace development of cloud and edge will enable applications of emerging technologies, improve computing power, and eventually reap bigger economic rewards. AI, IoT, cloud computing, and other emerging technologies will be the main drivers for IT spending in the future.
Inspur Empowers Computing Power Upgrade through Investment in Open Computing and Artificial Intelligence
The Report builds a comparative formula between computing power and economic development and serves as a reference for countries to improve their computing power and economic competitiveness. The digital economy is a significant component of GDP and computing is the foundation for the development of the digital economy.
As a leading force in emerging technologies, Inspur is the only server vendor who has joined all major open computing organizations, including OCP (Open Compute Project), ODCC and Open19, and is a Gold Member of OpenStack. Inspur leads the OpenRMC subproject, which focuses on next-generation data center management standards, and is an active member in OAM specification, the Scorpio Project, and the OTII for establishing edge computing standards.
In artificial intelligence, Inspur is the chair of SPEC ML, the Technical Committee on Machine Learning under the international evaluation organization SPEC. While working closely with leading tech companies in AI systems and applications, Inspur leads SPEC ML in the development of AI Test specifications and related benchmarks. As of today, Inspur has the most complete array of GPU servers in the industry with nearly 20 computing platforms supporting GPU numbers ranging from 4 to 64. Inspur also provides ultimate-design GPU servers such as the Inspur NF 5488A5, a 19-time record-setting server in the MLPerf benchmarks. Inspur currently offers full-stack AI capabilities including AI Computing Platform, AI Resource Suite, and Algorithm Toolkit.
Please click for more insights from the report.
About Inspur Information
Inspur Electronic Information Industry Co., LTD is a leading provider of data center infrastructure, cloud computing, and AI solutions, ranking among the world’s top 3 server manufacturers. Through engineering and innovation, Inspur delivers cutting-edge computing hardware design and extensive product offerings to address important technology arenas like open computing, cloud data center, AI and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle specific workloads and real-world challenges. To learn more, please go to en.inspur.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005020/en/
Contact information
Fiona Liu
Inspur Information
liuxuan01@inspur.com
Vivian Dadamio
vivian@allisonpr.com
+49 89 3888 920 10
+49 (0)176 32 666 550
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
